Medical/Pharmaceuticals

Lifespan Vision Ventures Co-Leads Sift Biosciences' $3.7M Pre-Seed Financing

NORWALK, Conn., Feb. 19, 2026 /PRNewswire/ -- Lifespan Vision Ventures, an investment firm focused on therapeutics that improve human healthspan, today announced that it has co-led Sift Biosciences' oversubscribed $3.7 million Pre-Seed financing alongside Freeflow Ventures, with participation fro...

2026-02-19 01:00 4407

Datasea Announces Foundational Research Breakthrough in Ultrasonic-Enhanced Nanoscale Precision Control

Establishing an Engineering-Level Core Technology for Next-Generation Semiconductor Manufacturing Applications BEIJING, Feb. 18, 2026 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada-based technology company specializing in acoustic high-tech solutions and 5G+AI ...

2026-02-18 22:30 7761

FDA Grants Breakthrough Device Designation to Two Rapid Tests Targeting Critical Drug-Resistant Pathogens

SANTA MARIA, Calif. and GUIPRY, France, Feb. 18, 2026 /PRNewswire/ -- In a major step forward against Antimicrobial Resistance (AMR), NG Biotech, in partnership with Hardy Diagnostics, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designations to...

2026-02-18 20:43 6494

Bioiberica Receives Frost & Sullivan's 2025 European New Product Innovation Award for Clinically Validated Native Type II Collagen

The recognition highlights Bioiberica's science-led innovation, clinical differentiation, and manufacturing excellence in the European innovative collagen market. SAN ANTONIO, Feb. 18, 2026 /PRNewswire/ -- Frost & Sullivan

2026-02-18 18:00 5939

Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging

MELBOURNE, Australia and INDIANAPOLIS, Feb. 18, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that it has submitted a marketing authorization application (MAA) in Europe for TLX101-Px (O-(2-[18F]fluoroethyl)-L-tyrosine, 18F-FET), its glioma (b...

2026-02-18 05:54 6489

FDA 510(k) Clearance Establishes Broad Intended Use for Copan's PhenoMATRIX®, Expanding Clinical Microbiology Capabilities

MURRIETA, Calif., Feb. 17, 2026 /PRNewswire/ -- Copan Group announced today that PhenoMATRIX®, its automated image assessment software used withWASPLab®

2026-02-17 23:00 7115

Metabolon's Metabolomics Platform Enables Largest Metabolomic Analysis to Date in CAR T-Cell Therapy, Revealing New Insights into Severe Neurotoxicity

Metabolomics-Derived Pathway Scores Outperform Inflammatory Protein Markers—Delivering Risk Prediction Where Proteomics Falls Short MORRISVILLE, N.C., Feb. 17, 2026 /PRNewswire/ -- Metabolon

2026-02-17 22:00 5465

Waters Introduces Next-Generation Microflow LC Columns with MaxPeak Premier Technology, Delivering Higher Sensitivity with Lower Sample and Solvent Usage

Headlines: * Delivers up to 2× higher sensitivity than stainless steel microflow columns, lowering detection and quantitation limits across high-throughput bioseparations, DMPK, and 'omics applications.1  * Uses up to 75% less sample than 2.1 mm I.D. columns, conserving precious materials su...

2026-02-17 21:00 5586

Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial

HIGHLIGHTS * Abstract outlining key findings from the Co-PSMA Investigator-Initiated Trial (IIT) has been released. * The study was led by Prof Louise Emmett at St Vincent's Hospital Sydney, and the abstract was accepted for oral presentation at the upcoming European Association of Urology (...

2026-02-16 22:03 8208

QuidelOrtho Enters Strategic Supply Agreement to Expand Global Immunoassay Portfolio

Agreement adds new analyzer platforms and expands assay menu across key international markets SAN DIEGO, Feb. 16, 2026 /PRNewswire/ -- QuidelOrtho has entered a long-term strategic supply agreement with Lifotronic Technology Co., Ltd. (Lifotronic Technology Co., Ltd., stock code: 688389), to exp...

2026-02-16 14:00 5436

Community Med Care's "Love & Share" CNY Blessing Campaign Gives the Gift of TCM Healing and Brings Hope to Children in Need

HONG KONG, Feb. 16, 2026 /PRNewswire/ -- This Lunar New Year, Community Med Care is turning seasonal blessings into lasting impact. The charity's "Love & Share" CNY Blessing Campaign invites the public to support its flagship program, "Stand Up with Love: Angel Mission", which provides free Tradi...

2026-02-16 09:00 6828

CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial

* CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA)to initiate a Phase II clinical trial inpatients with advanced solid tumors. This marks a significant milestone in the global development of thi...

2026-02-16 08:10 7062

Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Colorectal Cancer of Biparatopic HER2-targeting ADC JSKN003

SUZHOU, China, Feb. 14, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-005) of the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, for the treatment of ...

2026-02-14 20:58 10561

SingHealth Opens Community MRI Centre at Dunearn Village in Collaboration with United Imaging

SINGAPORE, Feb. 14, 2026 /PRNewswire/ -- SingHealth, Singapore's largest public healthcare cluster, has opened a new MRI centre at Dunearn Village, marking its first MRI facility located outside a hospital campus and extending diagnostic imaging services into the community. Developed in collabor...

2026-02-14 20:00 8856

HanchorBio Receives FDA Orphan Drug Designation for HCB101 in Gastric Cancer

First SIRPα-IgG4 Fc Fusion Protein Granted Orphan Status in Gastric Cancer TAIPEI, SHANGHAI and SAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases,...

2026-02-13 14:04 6308

Omics Empower Hong Kong Launches Xenium™ In Situ Spatial Transcriptomics Services

HONG KONG, Feb. 13, 2026 /PRNewswire/ -- Omics Empower, a global life science service provider specializing in single-cell sequencing and spatial transcriptomics, announced that Xenium™ In Situ Spatial Transcriptomics services are now available at its Hong Kong Science Park laboratory. Since the...

2026-02-13 14:00 4692

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer

SAN FRANCISCO and SUZHOU, China, Feb. 12, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent",HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ...

2026-02-13 08:00 6530

Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia

- Comprehensive review of recent milestones highlights statistically significant efficacy in prostate cancer prevention, discovery of novel lipid-modulating properties, and the execution of high-value commercial partnerships in South Korea and Vietnam. NEW TAIPEI CITY, Feb. 13, 2026 /PRNewswire/...

2026-02-13 08:00 11687

Datasea Reports Second Fiscal Quarter 2026 Results

Gross Profit Increased 284.4% Year-over-Year and Gross Margin Increases 730 Basis Points to 8.8% BEIJING, Feb. 12, 2026 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), aNevada-based technology enterprise engaged in acoustic technologies and 5G+AI multimodal digitalizati...

2026-02-12 22:20 13749

Sanyou Biopharmaceuticals Lang Guojun: Making Innovative Biologics R&D Easier for Clients Worldwide

Tagline: Empowering Global Innovative Biologics R&D through Ecosystem Strength SHANGHAI, Feb. 12, 2026 /PRNewswire/ -- On February 8, at the 2026 China New Drug Source Innovation Forum inShanghai, Lang Guojun, Founder & CEO of Sanyou Biopharmaceuticals, shared the story of a vision that began ten...

2026-02-12 22:00 5836
1 ... 11121314151617 ... 647